-+ 0.00%
-+ 0.00%
-+ 0.00%

Monopar presents Phase 2 data showing ALXN1840 stabilizes liver disease in Wilson patients at EASL 2026

PUBT·06/01/2026 11:04:41
Listen to the news
Monopar presents Phase 2 data showing ALXN1840 stabilizes liver disease in Wilson patients at EASL 2026
  • Monopar highlighted Phase 2 ALXN1840 data already presented at EASL 2026 in treatment-experienced Wilson disease patients.
  • The 48-week study showed liver disease generally stabilized, with some patients showing improvement on biopsy assessments.
  • Patients also showed improvement in neurological symptoms, with gains in overall clinical status and reported quality of life.
  • Safety was broadly consistent with tolerability expectations, with most side effects described as nonserious.
  • The readout supports ALXN1840’s positioning for Wilson disease patients inadequately served by current standard therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010700PRIMZONEFULLFEED9729413) on June 01, 2026, and is solely responsible for the information contained therein.